Supplements

Daridorexant 25 mg improves objective and subjective sleep metrics in insomnia patients over 3 months

In a meta-analysis of 6 RCTs with 2905 insomnia patients, daridorexant 25 mg showed sustained efficacy in objective sleep measures (LPS, WASO) at 3 months and in subjective total sleep time (sTST) at 3 months (SMD 0.25 [0.14, 0.36], P < 0.0001). The 25 mg dose was associated with an increased risk of adverse events of special interest (AESIs) compared to placebo (RR 4.00 [1.64, 9.76], P = 0.002).

1 min read•Updated Jul 25, 2026•0 RCTs•1 Meta-analyses•View structured evidence →
Evidence Score49/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Daridorexant 25 mg improves objective and subjective sleep metrics in insomnia patients over 3 months The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).

The Claim

Daridorexant 25 mg improves objective and subjective sleep metrics in insomnia patients over 3 months

This conclusion is most relevant to: 2905 patients with insomnia from 6 randomized controlled trials.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸The "efficacy window" phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis. (Frontiers in pharmacology, 2026) —

How It Works

The proposed biological pathway:

  • ▸Daridorexant binds to orexin receptors
  • ▸Blocks orexin signaling
  • ▸Reduces wakefulness
  • ▸Improves sleep maintenance and onset

Who Might Benefit

Evidence fit by population:

  • ▸2905 patients with insomnia from 6 randomized controlled trials

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Only 5 articles and 6 RCTs were included, limiting generalizability
  • ▸Heterogeneity was observed in some subjective outcomes (I2 = 52% for sTST)
  • ▸The increased risk of AESIs with 25 mg requires further investigation

Frequently Asked Questions

What is the efficacy window for daridorexant?▼

The efficacy is dose-dependent, with 25 mg and 50 mg showing short-term (1 month) benefits, and 25 mg sustaining efficacy in objective metrics up to 3 months.

Is daridorexant 25 mg safe for long-term use?▼

Overall safety is comparable to placebo, but the 25 mg dose significantly increases the risk of adverse events of special interest (AESIs) such as potential safety signals.

How does daridorexant compare to placebo for subjective sleep?▼

At 1 month, daridorexant outperformed placebo on most subjective indicators; at 3 months, only the 25 mg dose remained effective for subjective total sleep time.

What objective sleep measures improved with daridorexant?▼

Latency to persistent sleep (LPS) and wake time after sleep onset (WASO) improved with daridorexant compared to placebo at 1-2 days, 1 month, and for 25 mg at 3 months.

References

  1. 1.Wang X, Wang Y, Wang M, Zheng Q, Li M, Zheng Y, Gao Y, Song W, Bo J, Guo H, Wang Z, Luo S. “The "efficacy window" phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis..” Frontiers in pharmacology, 2026. PMID: 42453571 DOI: 10.3389/fphar.2026.1847130
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.